Compare DVA & ALGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DVA | ALGN |
|---|---|---|
| Founded | 1994 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9B | 12.7B |
| IPO Year | 2003 | 2000 |
| Metric | DVA | ALGN |
|---|---|---|
| Price | $180.74 | $180.19 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 12 |
| Target Price | $156.75 | ★ $199.82 |
| AVG Volume (30 Days) | ★ 958.3K | 860.9K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.53 |
| EPS | ★ 6.86 | 3.09 |
| Revenue | ★ $13,643,069,000.00 | $387,126,000.00 |
| Revenue This Year | $3.85 | $5.78 |
| Revenue Next Year | $3.07 | $4.62 |
| P/E Ratio | ★ $26.11 | $57.02 |
| Revenue Growth | 6.46 | ★ 23.95 |
| 52 Week Low | $101.00 | $122.00 |
| 52 Week High | $247.49 | $200.44 |
| Indicator | DVA | ALGN |
|---|---|---|
| Relative Strength Index (RSI) | 27.40 | 57.68 |
| Support Level | $176.59 | $164.70 |
| Resistance Level | $202.63 | $186.82 |
| Average True Range (ATR) | 8.14 | 6.46 |
| MACD | -5.52 | 0.76 |
| Stochastic Oscillator | 6.65 | 69.87 |
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.